How to Use the Medicare GLP-1 Bridge on July 1: Eligibility, Prior Authorization, Pharmacy Steps, and Backup Options

Starting July 1, 2026, eligible Medicare Part D beneficiaries can use the Medicare GLP-1 Bridge to get certain obesity GLP-1 prescriptions for a fixed $50 copay per monthly supply. The Bridge runs through December 31, 2027.

The important catch: this is not automatic Part D coverage. CMS says the Bridge operates outside the ordinary Part D benefit payment flow. In 2026, CMS uses a single central processor for prior authorization, claims adjudication, and pharmacy payment.

You do not register or opt in yourself. CMS says beneficiaries do not need to take action before launch. In practice, the work is making sure the medical file, indication, drug formulation, prior authorization, and pharmacy claim all line up once July 1 arrives.

Use the Bridge only if the requested use is weight management and the patient meets the criteria. If the GLP-1 is prescribed for a Part D coverable indication such as type 2 diabetes, obstructive sleep apnea, noncirrhotic MASH, or Wegovy cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, the claim should use ordinary Part D instead.

Before assuming $50 access, verify five things: 2026 Part D enrollment, Bridge-eligible plan type, weight-management indication, initiation BMI and diagnosis, and the exact product formulation.

For the broader overview, read Medicare GLP-1 Bridge coverage 2026. This article is the execution checklist.

Bridge Eligibility Checklist

Eligible plan types include standalone prescription drug plans and Medicare Advantage coordinated care plans with prescription drug coverage, including HMO, HMO-POS, local PPO, and regional PPO MA-PD plans for calendar year 2026.

CMS also lists Special Needs Plans, employer or union group waiver plans, and LI NET as eligible if the other Bridge criteria are met.

Excluded plan types include private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans, unless the beneficiary also has a standalone PDP where applicable.

Dually eligible beneficiaries can use the Bridge if they are enrolled in an eligible Part D plan type and meet the prior authorization criteria. TRICARE For Life beneficiaries qualify only if they are also enrolled in a Bridge-eligible Part D plan type and meet the same prior authorization criteria.

The prescriber also matters. CMS says the provider does not need to be enrolled in Medicare to prescribe or submit prior authorization for Bridge products, but the provider must not be on the Preclusion List.

The cleanest pre-launch move is simple: call the Part D plan or Medicare Advantage plan and confirm the exact 2026 plan type. Do not stop at “I have Medicare.” The Bridge depends on plan type, clinical criteria, indication, product, and claim routing.

Clinical Criteria the Prescriber Must Attest

The Bridge is for GLP-1 use to reduce excess body weight and maintain weight reduction with current and ongoing lifestyle modification. CMS specifically names structured nutrition and physical activity consistent with the FDA-approved label.

The patient must be at least 18 and meet one of three clinical paths at the time GLP-1 therapy was initiated.

First path: BMI of 35 or higher at initiation.

Second path: BMI of 30 or higher at initiation plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above. CMS defines uncontrolled hypertension as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg despite concurrent treatment with two antihypertensive medications.

Third path: BMI of 27 or higher at initiation plus a diagnosis of prediabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.

The initiation-date rule is useful for patients already on therapy. CMS says eligibility is assessed at the time GLP-1 therapy was initiated, including therapy that started before Part D enrollment or before July 1, 2026. CMS gives this example: a patient with BMI 37 in September 2024 and BMI 34 in July 2026 can still meet the BMI 35 or higher initiation criterion.

Ask the prescriber to document initiation BMI, current BMI, diagnosis, comorbidities, prior GLP-1 start date if any, ongoing lifestyle modification, and why the selected product fits the FDA-approved label.

Which Drugs and Formulations Qualify

CMS lists the eligible Bridge products for weight reduction as Foundayo, Wegovy injection and tablets, and Zepbound KwikPen.

Beginning July 1, 2026, all formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound are available through the Bridge for eligible beneficiaries.

Zepbound single-dose vials and single-dose pens are not available through the Bridge. This is a major practical detail for people comparing Bridge access against LillyDirect or other brand cash-pay vial routes.

CMS says the product and NDC list may change during the Bridge, so the prescriber and pharmacy should verify the current list before filling.

Current NDC list from CMS:

Foundayo: 0002-4178-31, 0002-4503-31, 0002-4794-31, 0002-4803-31, 0002-4839-31, 0002-4953-31.

Wegovy: 0169-4525-14, 0169-4505-14, 0169-4501-14, 0169-4517-14, 0169-4524-14, 0169-4415-31, 0169-4404-31, 0169-4409-31, 0169-4425-31, 0169-4572-14.

Zepbound KwikPen: 0002-3566-11, 0002-3555-11, 0002-3544-11, 0002-3533-11, 0002-3522-11, 0002-3511-11.

For drug background, use semaglutide, tirzepatide, and orforglipron. Orforglipron is useful context for future oral GLP-1 competition, but it is not listed here as a Bridge product.

July 1 Step-by-Step Workflow

1. Confirm the patient is enrolled in an eligible Part D plan type for 2026. Standalone PDP and many MA-PD coordinated care plans can qualify. Some plan types cannot.

1. Confirm the requested use is weight management. CMS says type 2 diabetes, obstructive sleep apnea, and noncirrhotic MASH indications are eligible for Part D coverage, so they do not use the Bridge path. CMS also names Wegovy cardiovascular risk reduction for adults with established cardiovascular disease and obesity or overweight as a Part D covered-indication example.

1. Build the prescriber file before launch. Include initiation BMI, current BMI, diagnosis, comorbidities, prior GLP-1 start date if any, lifestyle modification, medication history, and product rationale.

1. Choose a Bridge-eligible product and formulation before the prescription is sent. For Zepbound, that means KwikPen, not single-dose vials or single-dose pens.

1. On or after July 1, 2026, the provider submits the prescription and prior authorization request. CMS says prior authorization requests will not be accepted or processed before July 1, 2026. Requests can be submitted electronically or by fax using the Medicare GLP-1 Bridge prior authorization form. CMS strongly encourages electronic submission.

1. Once approved, the pharmacy fills through the Bridge flow. CMS uses a single central processor in 2026 for prior authorization, claims adjudication, and pharmacy payment.

1. If the pharmacy or prescriber cannot route the claim, ask whether they are using Medicare GLP-1 Bridge BIN 028918 and PCN MEDDGLP1BR, reported by NCPA from CMS guidance.

Cost Comparison and Payment Traps

The Bridge price is the headline: eligible beneficiaries pay a fixed $50 copay per monthly supply.

KFF says manufacturers agreed to provide eligible GLP-1s under the Bridge at a $245 net price per monthly supply. KFF also says pharmacies collect the $50 copayment and submit claims to a central processor for reimbursement.

The payment trap is that the Bridge is outside the normal Part D cost-sharing path. CMS and KFF say the $50 copay does not count toward the Part D deductible or true out-of-pocket costs. KFF says it does not count toward the $2,100 Part D out-of-pocket maximum in 2026 or the $2,400 maximum in 2027. CMS also says low-income subsidy cost-sharing help does not apply to any portion of the Bridge copay.

That still makes the Bridge the lowest-price path for eligible obesity GLP-1 access. It just should not be confused with Part D spending progress.

Simple comparison:

Bridge: $50/month if eligible.

Manufacturer self-pay options: vary by drug, dose, formulation, and program terms.

Compounded semaglutide online: PeptidePub pricing pages often track about $149 to $299/month. Use cheapest semaglutide online.

Compounded tirzepatide online: PeptidePub pricing pages often track about $249 to $349/month. Use compounded tirzepatide cost and best online tirzepatide programs.

Brand retail without coverage or support can exceed $1,000/month.

Backup Options if the Bridge Does Not Fit

If the Bridge fails, first identify why. A plan-type problem is different from a missing BMI record, an excluded formulation, a Part D covered indication, or a prior authorization file that was submitted too early.

If the diagnosis route is type 2 diabetes, obstructive sleep apnea, noncirrhotic MASH, or another Part D coverable use, ask about the ordinary Part D pathway instead of the Bridge.

If the issue is product formulation, check the prescription. CMS includes Zepbound KwikPen, but not Zepbound single-dose vials or single-dose pens. Bridge-ineligible vial users should compare LillyDirect or other brand self-pay routes rather than assuming the $50 Bridge price applies.

If the issue is missing clinical support, the prescriber file may need initiation BMI, current BMI, diagnosis, comorbidity documentation, prior start date, structured nutrition and physical activity, and a clear label-based rationale.

If none of that fixes access, compare cash-pay options. For semaglutide, use cheapest semaglutide online. For tirzepatide, use compounded tirzepatide cost and best online tirzepatide programs. For broader provider shopping, use best online weight-loss program and GLP-1 without insurance.

Cash-pay providers to compare include Eden Health, SkinnyRx, Direct Meds, and Medvi.

Keep the safety distinction clear: compounded GLP-1s are not FDA-approved finished products and should not be described as equivalent to Wegovy, Zepbound, or Foundayo.

FAQ

Do I need to sign up for the Medicare GLP-1 Bridge? No. CMS says beneficiaries are not required to register or opt in and do not need to take action before launch. The provider and pharmacy workflow matters once the program begins.

Can my doctor submit the Bridge prior authorization before July 1, 2026? No. CMS says prior authorization requests will not be accepted or processed before July 1, 2026.

What if I already started a GLP-1 before Medicare or before July 1? CMS says clinical criteria are assessed at the time GLP-1 therapy was initiated, including therapy started before Part D enrollment or before the Bridge launch. That can help patients whose current BMI is lower because treatment already worked.

Does the $50 copay count toward my Part D deductible or out-of-pocket maximum? No. CMS says it does not count toward TrOOP. KFF says it does not count toward the $2,100 Part D cap in 2026 or the $2,400 cap in 2027.

Can I use the Bridge for Ozempic or Mounjaro?

Not under the CMS list reviewed here. The listed Bridge products for weight reduction are Foundayo, Wegovy injection and tablets, and Zepbound KwikPen.

Bottom Line

The Medicare GLP-1 Bridge is the clear lowest-price route for eligible beneficiaries at $50/month, but it is temporary, criteria-based, outside Part D, and not available for every GLP-1 or every diagnosis.

Before July 1, confirm the Part D plan type, weight-management indication, initiation BMI and diagnosis, eligible product formulation, prescriber prior authorization readiness, and pharmacy claim routing.

If the Bridge does not fit, do not let the search dead-end. Compare GLP-1 without insurance, cheapest semaglutide online, compounded tirzepatide cost, and best online weight-loss program.